$SLQT

Follow the Trend Seeker: Beaten-Down SelectQuote Stock Surges 54% in 1 Month as Barchart’s Data Signals ‘Buy’

SelectQuote (SLQT) stock has surged 54% in the last month after Barchart's Trend Seeker issued a "Buy" signal on April 17, despite a 72% loss over the past year. Analysts project significant earnings growth for next year, though current Wall Street sentiment is mixed. The article suggests SLQT as a speculative rebound candidate for investors looking for beaten-down stocks starting to recover.

Original reporting
Barchart.com · Jim Van Meerten
Published Apr 28, 2026, 2:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 28, 2026, 3:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Follow the Trend Seeker: Beaten-Down SelectQuote Stock Surges 54% in 1 Month as Barchart’s Data Signals ‘Buy’ — source image
Decision brief

The 30-second read

$SLQTBullishMed
01

Why it matters

The positive technical signals could attract short-term trading interest, but fundamental concerns remain.

02

Market read

The news highlights a technical rebound in SLQT, which may influence short-term trading activity but has limited impact on broader market fundamentals.

03

What to watch

Potential market volatility, sector-wide risks, and the possibility that the buy signal may be a false positive.

Timing: Short-term (next 1-3 months)

Background

SelectQuote has been underperforming over the past year, with a 72% decline, but recent technical signals and analyst projections suggest a potential turnaround.

Company-level read

Ticker impact

$SLQTBullishMedium confidence
Context

Primary focus of the news due to recent surge and buy signal

Expected impact

Moderate upward movement in the near term, potential for continued rebound if technical and fundamental factors align

Evidence & confidence

The recent surge and buy signal support a bullish outlook, but the stock's prior decline and mixed Wall Street sentiment introduce uncertainty.

Market effects

The surge in SLQT may positively influence sentiment in the insurance and financial services sectors, especially among beaten-down stocks

Limited regional impact, primarily affecting US-based financial stocks

Minimal

Counterpoint

The recent surge may be a short-term technical bounce without fundamental support; caution is advised before committing significant capital.

Key entities

  • SelectQuote

    An insurance technology company with recent stock performance challenges.

  • Barchart

    Provider of technical signals and market data.

Related articles

$SLQTHighAI 8/10

Why is Selectquote stock sliding today?

Selectquote (SLQT) shares dropped 16.59% in pre-market trading to $0.643 after missing Q4 2026 earnings and revenue estimates. The company reported a loss of $0.19 per share and $321.7M in revenue, while FY2027 guidance of $1.35B-$1.45B fell below consensus. Analysts had already lowered ratings due to sector headwinds, including Medicare Advantage marketing cuts and reimbursement pressures.

$RBAHigh

Why This U.S. Auto Retail Stock is Barclays’ Top Pick Right Now

Barclays named RB Global Inc (RBA) its top U.S. auto retail pick, citing an attractive valuation at 12.7x EV/EBITDA, market share gains, and cyclical improvements in its Heavy Equipment & Transportation segment. RBA reported Q2 2026 revenue of $1.32B, beating estimates, with 11% gross transaction value growth. Barclays expects RBA to gain market share from Copart Inc (CPRT) in the salvage vehicle auction market.

$GHHighAI 8/10

Guardant ordered to pay $245m in DNA sequencing patent dispute

Guardant Health was ordered to pay $245.2m to TwinStrand Biosciences and the University of Washington for patent infringement. The ruling covers 11 products, including Guardant360 CDx, and includes damages, royalties, and interest. Guardant plans to appeal, while TwinStrand affirms its commitment to its intellectual property.

$KURAMed

Why is Kura Oncology stock surging today?

Kura Oncology's stock rose 11.6% in pre-market trading after CEO Troy Wilson bought 100,000 shares for $1.24 million, his second large purchase in a week. Analysts Citigroup and Jefferies reaffirmed positive ratings, citing strong commercial momentum for KOMZIFTI and Q2 earnings beat. The stock surpassed its 52-week high of $12.90.

$BEMed

Nancy Pelosi Made Millions On Nvidia Options. Now She’s Betting $3 Million On 1 AI Energy Stock

Paul Pelosi, spouse of House Speaker Nancy Pelosi, acquired 15,000 shares and 200 call options of Bloom Energy (BE) in July 2026, with a potential investment ranging from $3 million to $12 million. Bloom Energy reported Q2 2026 revenue of $1.065 billion, up 165.5% year-over-year, and raised full-year guidance to $3.9 billion to $4.2 billion. The stock closed at $204.02 on August 24, 2026, up 134.8% year-to-date. The Pelosi household also added to an existing Intel (INTC) position.